Strides Pharma Science (NSE:STAR) Cyclically Adjusted PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
65 GF Score
Price ₹1,028.50
GF Value ₹840.55
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Strides Pharma Science Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Strides Pharma Science  (NSE:STAR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Strides Pharma Science Cyclically Adjusted PB Ratio Related Terms


Strides Pharma Science Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Cyclically Adjusted PB Ratio Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.36 1.02 1.95 2.68

Strides Pharma Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.33 0.00 2.68 0.00

NSE:STAR vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Cyclically Adjusted PB Ratio falls into.


NSE:STAR
65GF Score
Strides Pharma Science Ltd NSE:STAR
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Strides Pharma Science's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Strides Pharma Science's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/166.1454*166.1454
=0.000

Current CPI (Jun. 2026) = 166.1454.

Strides Pharma Science Quarterly Data

Book Value per Share CPI Adj_Book
201609 290.006 105.961 454.725
201612 0.000 105.196 0.000
201703 307.960 105.196 486.389
201706 0.000 107.109 0.000
201709 303.658 109.021 462.766
201712 0.000 109.404 0.000
201803 275.269 109.786 416.579
201806 0.000 111.317 0.000
201809 264.059 115.142 381.027
201812 0.000 115.142 0.000
201903 295.783 118.202 415.754
201906 0.000 120.880 0.000
201909 290.109 123.175 391.315
201912 0.000 126.235 0.000
202003 282.188 124.705 375.961
202006 0.000 127.000 0.000
202009 300.004 130.118 383.070
202012 0.000 130.889 0.000
202103 309.615 131.771 390.384
202106 0.000 134.084 0.000
202109 267.951 135.847 327.713
202112 0.000 138.161 0.000
202203 262.750 138.822 314.466
202206 0.000 142.347 0.000
202209 258.209 144.661 296.557
202212 0.000 145.763 0.000
202303 244.982 146.865 277.144
202306 0.000 150.280 0.000
202309 227.327 151.492 249.316
202312 0.000 152.924 0.000
202403 231.291 153.035 251.106
202406 0.000 155.789 0.000
202409 247.006 157.882 259.934
202412 0.000 158.323 0.000
202503 276.882 157.552 291.985
202506 0.000 159.755 0.000
202509 298.986 162.289 306.090
202512 0.000 163.281 0.000
202603 337.145 164.272 340.989
202606 0.000 166.145 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,028.50 is trading 22.4% above its estimated GF Value™ of ₹840.55. GuruFocus considers Strides Pharma Science to be Modestly Overvalued.

Key valuation signals for NSE:STAR:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹840.55 vs. price of ₹1,028.50 (22.4% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
65GF Score

Get the complete analysis for NSE:STAR

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,028.50
Price
₹840.55
GF Value